Golden State Equity Partners Raises Holdings in Becton, Dickinson and Company (NYSE:BDX)

Golden State Equity Partners boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,707 shares of the medical instruments supplier’s stock after acquiring an additional 143 shares during the quarter. Golden State Equity Partners’ holdings in Becton, Dickinson and Company were worth $416,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of BDX. OFI Invest Asset Management purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. Fortitude Family Office LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $35,000. Venturi Wealth Management LLC lifted its holdings in Becton, Dickinson and Company by 552.0% in the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 138 shares during the period. Arlington Trust Co LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $41,000. Finally, Headlands Technologies LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $55,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Up 0.5 %

Shares of NYSE:BDX opened at $231.55 on Friday. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The firm has a market capitalization of $66.89 billion, a P/E ratio of 54.87, a P/E/G ratio of 1.91 and a beta of 0.43. The stock has a 50 day moving average price of $239.24 and a 200-day moving average price of $241.24. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.73 billion. During the same quarter last year, the company earned $2.98 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Insider Activity at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.31% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Barclays increased their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Raymond James increased their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.